How many drugs treat Articular gout?

Drug Landscape tracks 10 marketed treatments for Articular gout (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Articular gout?

Most recent: Aloprim — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/articular-gout.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Articular gout — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Articular gout (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Articular gout, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ilaris	CANAKINUMAB	Novartis Pharms	Non-Standardized Plant Allergenic Extract [EPC]	Interleukin-1 beta	2009-01-01
Aloprim	ALLOPURINOL	Casper Pharma Llc	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	1966-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Solu-Cortef	hydrocortisone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
Col-Probenecid	probenecid	Pfizer Inc.	probenecid	Carbonic anhydrase 9	1951-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-13 — Aloprim · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Articular gout
Generic (originally Schering) · 2 drugs in Articular gout
Pfizer · 2 drugs in Articular gout
Generic (originally Merck/Upjohn) · 1 drug in Articular gout
Generic (originally Upjohn/Pfizer) · 1 drug in Articular gout
Hannover Medical School · 1 drug in Articular gout
Leiden University Medical Center · 1 drug in Articular gout
Novartis Pharms · 1 drug in Articular gout
Pfizer Inc. · 1 drug in Articular gout
University of Zurich · 1 drug in Articular gout
Wen Zhang · 1 drug in Articular gout
Casper Pharma Llc · 1 drug in Articular gout

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Articular gout:

Cite this brief

Drug Landscape (2026). Articular gout — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/articular-gout. Accessed 2026-06-10.

Articular gout full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing